John O'Grady

Dr. John O'Grady

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JOJohn O'Grady
John O'Grady
EOEibhlís O'connor
Eibhlís O'connor
FSFergus Shanahan
Fergus Shanahan
Summary: Background: Explanations for the health benefits of dietary fibre have, in the past, been inconsistent and studies of the physiological effects of dietary fibre were, perhaps, directed at the wrong read‐outs. Confounding factors included a failure to appreciate the molecular diversity and varied properties of fibre‐types and the role of fibre as a substrate for microbial metabolism in the gut.Aim: To present a modern perspective on fibre science and to encourage clinicians to re‐consider the health impact of dietary fibre and how best to approach adjustments in dietary consumption.Methods: This perspective is drawn selectively from recent microbiome science; no attempt was made to perform an exhaustive review of all articles related to every aspect of dietary fibre.Results: Advances in microbiome science have revealed not only the functional impact of dietary fibre on the composition and function of the microbiota but have also demonstrated the physiologic responses to microbial‐derived metabolites from fibre digestion. Moreover, studies have shown the personalised nature of host responses to dietary fibre intervention, with outcomes being dependent on individual pre‐treatment gut ecology.Conclusions: The physical properties of dietary fibres are important for homeostasis within the gut, but the predominant health benefits extend beyond the gut to enhanced metabolic welfare, including protection against obesity and related metabolic diseases. Fibre is a form of functional food joining a growing list of examples of diet‐microbe‐host interactions which link microbe‐host metabolic and immune cascades.

21 February 2020 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
JOJohn O'Grady
John O'Grady
CMClodagh L. Murphy
Clodagh L. Murphy
LBLillian Barry
Lillian Barry
FSFergus Shanahan
Fergus Shanahan
MBMartin Buckley
Martin Buckley
Background and study aims Determining the etiology and location of gastrointestinal motility disorders can be challenging. A range of investigations targeting specific areas of gastrointestinal transit are available, but many provide clinical data for a given gastrointestinal region alone or for non-specific whole gut transit, and are otherwise of limited use. Video capsule endoscopy allows endoscopic visualisation of the entire gastrointestinal tract, and may also provide more specific data for regional transit time abnormalities. Patients and methods Data from video capsules ingested by 71 ambulatory healthy subjects were recorded and analyzed to determine gastric and small bowel transit times in the fasting state. Results Median, and interquartile range (IQR), gastric transit time was 22 (10–48) minutes, and median (IQR) small bowel transit time was 198.5 (157–240.5) minutes. Conclusion These data, for the first time to our knowledge, provide references for gastrointestinal transit times among healthy ambulatory subjects using video capsule endoscopy. This potentially strengthens clinical use of video capsule endoscopy in the investigation of patients with suspected gastrointestinal motility disorders.

1 January 2011 in HPB
Verified
Journal Article
Closed access
PDF file
SYSatoshi Yokoyama
Satoshi Yokoyama
Adam BartlettAdam Bartlett
Adam Bartlett
FDFaisal S. Dar
Faisal S. Dar
MHMichael Heneghan
Michael Heneghan
JOJohn O'Grady
John O'Grady
NHNigel Heaton
Nigel Heaton

1 March 1991 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
HSHelmut Sinzinger
Helmut Sinzinger
JKJosef Kaliman
Josef Kaliman
JOJohn O'Grady
John O'Grady

1 January 1993 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
MCMichelle Collins
Michelle Collins
KCK. Carter
K. Carter
ABAlan Baillie
Alan Baillie
JOJohn O'Grady
John O'Grady
The pharmacokinetics and tissue distribution of antimony after the administration of sodium stibogluconate in a free form or entrapped in vesicles prepared from non-ionic surfactant were studied in the dog. Animals were given either one or two intravenous bolus injection(s) equivalent to 45 mg Sb kg-1 as free drug or 0.625 or 0.685 mg Sb kg-1 as vesicular drug. Blood samples were taken at various times after dosing and antimony levels in various tissues were determined at 3 h, 48 h and 6 days after dosing. After free stibogluconate antimony clearance from the blood occurred in a rapid elimination phase with a blood half-life of 0.58±0.08 h. This rapid elimination phase did not occur after vesicular drug. Both drug preparations gave similar antimony levels in the spleen, liver and femur and humerus bone marrow at all time points assessed even though the vesicular dose was one-seventieth of the free drug dose. After the free drug there was marked urinary excretion of antimony and, as a result, increased kidney loading at the expense of other tissue. Vesicle-mediated drug delivery suppressed renal excretion and a much greater proportion of the antimony dose was recovered from tissue than was obtained after free drug. A hypothesis is presented to account for the differences in tissue antimony concentrations produced by the two formulations.

8 November 2018 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
JOJohn O'Grady
John O'Grady
FSFergus Shanahan
Fergus Shanahan